Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQUAx: AAV2hAQP1 for Radiation-Induced Xerostomia
NCT04043104Phase 1Completed
- Sponsor
- MeiraGTx
- Start
- Jun 2019
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
Phase 1, open-label trial of AAV-AQP1 in radiation-induced xerostomia and Parotid gland hypofunction (8 arms), sponsored by MeiraGTx. Primary endpoint: Safety of AAV2hAQP1 at 1 year. Started Jun 2019; status: completed.
02
Drugs
AAV-AQP1
03
Conditions
radiation-induced xerostomiaParotid gland hypofunction
Beyond the preview
Go deeper on NCT04043104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04043104.